JP2020525426A5 - - Google Patents

Download PDF

Info

Publication number
JP2020525426A5
JP2020525426A5 JP2019570461A JP2019570461A JP2020525426A5 JP 2020525426 A5 JP2020525426 A5 JP 2020525426A5 JP 2019570461 A JP2019570461 A JP 2019570461A JP 2019570461 A JP2019570461 A JP 2019570461A JP 2020525426 A5 JP2020525426 A5 JP 2020525426A5
Authority
JP
Japan
Prior art keywords
compound
formula
reducing agent
reacting
converting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019570461A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020525426A (ja
JP7224307B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/039148 external-priority patent/WO2018237350A1/en
Publication of JP2020525426A publication Critical patent/JP2020525426A/ja
Publication of JP2020525426A5 publication Critical patent/JP2020525426A5/ja
Application granted granted Critical
Publication of JP7224307B2 publication Critical patent/JP7224307B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019570461A 2017-06-23 2018-06-22 胆汁酸誘導体の調製のための方法及び中間体 Active JP7224307B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762523937P 2017-06-23 2017-06-23
US62/523,937 2017-06-23
PCT/US2018/039148 WO2018237350A1 (en) 2017-06-23 2018-06-22 METHODS AND INTERMEDIATES FOR PREPARING BILARY ACID DERIVATIVES

Publications (3)

Publication Number Publication Date
JP2020525426A JP2020525426A (ja) 2020-08-27
JP2020525426A5 true JP2020525426A5 (https=) 2021-07-26
JP7224307B2 JP7224307B2 (ja) 2023-02-17

Family

ID=64691408

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019570461A Active JP7224307B2 (ja) 2017-06-23 2018-06-22 胆汁酸誘導体の調製のための方法及び中間体

Country Status (10)

Country Link
US (2) US11066437B2 (https=)
EP (1) EP3642217A4 (https=)
JP (1) JP7224307B2 (https=)
KR (2) KR20250109791A (https=)
CN (1) CN110945006A (https=)
AU (1) AU2018288883B2 (https=)
BR (1) BR112019027458A2 (https=)
CA (1) CA3067219A1 (https=)
IL (3) IL326587A (https=)
WO (1) WO2018237350A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2848212C (en) 2011-09-08 2022-03-29 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
PT2968369T (pt) 2013-03-13 2018-12-05 Sage Therapeutics Inc Esteroides neuroativos e métodos para o seu uso
US10259840B2 (en) 2014-06-18 2019-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
HUE071964T2 (hu) 2015-07-06 2025-10-28 Sage Therapeutics Inc Oxiszterolok és alkalmazási eljárásaik
EP3828194B1 (en) 2015-07-06 2025-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CA2991311C (en) 2015-07-06 2025-05-06 Sage Therapeutics, Inc. OXYSTEROLS AND THEIR METHODS OF USE
EP3981779A1 (en) * 2015-10-07 2022-04-13 Intercept Pharmaceuticals, Inc. Farnesoid x receptor modulators
SMT202200300T1 (it) 2016-04-01 2022-09-14 Sage Therapeutics Inc Ossisteroli e relativi metodi d'uso
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
ES2884071T3 (es) 2016-07-07 2021-12-10 Sage Therapeutics Inc 24-hidroxiesteroles sustituidos en 11 para el tratamiento de afecciones relacionadas con NMDA
ES2935057T3 (es) 2016-09-30 2023-03-01 Sage Therapeutics Inc C7 oxisteroles sustituidos y estos compuestos para su uso como moduladores de la NMDA
RU2019115113A (ru) 2016-10-18 2020-11-24 Сейдж Терапьютикс, Инк. Оксистеролы и способы их применения
KR20230051723A (ko) 2016-10-18 2023-04-18 세이지 테라퓨틱스, 인크. 옥시스테롤 및 그의 사용 방법
KR20220150270A (ko) 2019-10-07 2022-11-10 칼리오페, 인크. Gpr119 효능제
US20230128984A1 (en) * 2020-01-31 2023-04-27 The Johns Hopkins University Bile acid-gcpii inhibitor conjugates to treat inflammatory diseases, including inflammatory bowel disease (ibd)
TW202140440A (zh) 2020-02-28 2021-11-01 美商克力歐普股份有限公司 Gpr40激動劑
US12215127B2 (en) 2020-04-17 2025-02-04 Cornell University Compositions and methods for profiling of gut microbiota-associated bile salt hydrolase (BSH) activity
WO2021236617A1 (en) 2020-05-19 2021-11-25 Kallyope, Inc. Ampk activators
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂
CN112795615A (zh) * 2021-02-03 2021-05-14 湖南醇康医药科技有限公司 一种诱变菌种以及微生物发酵制备熊去氧胆酸的方法
WO2023288123A1 (en) * 2021-07-16 2023-01-19 Interecept Pharmaceuticals, Inc. Methods and intermediates for the preparation of 3.alpha.,7.alpha.,11.beta.-trihydroxy-6.alpha.-ethyl-5.beta.-cholan-24-oic acid
CN114045239B (zh) * 2021-11-08 2023-09-29 浙江树人学院(浙江树人大学) 具有二甲基乙酰胺降解能力的泛养副球菌ybh-7及应用
US20250288600A1 (en) * 2022-04-21 2025-09-18 Intercept Pharmaceuticals, Inc. Uses of farnesoid x receptor agonists
WO2024163640A2 (en) * 2023-02-01 2024-08-08 Intercept Pharmaceuticals, Inc. Methods and intermediates for the preparation of bile acid derivatives

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2403683A (en) * 1942-04-25 1946-07-09 Relchstein Tadeus Compounds of the cyclopentanopolyhydrophenanthrene series and process of making same
US2554882A (en) * 1943-02-04 1951-05-29 Reichstein Tadeus 3-hydroxy-11-ketoetiocholanic acid and its esters
US3277121A (en) * 1964-05-04 1966-10-04 Canada Packers Ltd Conversion of delta11-steroids to 11-oxygenated steroids
DE3040634A1 (de) * 1980-10-29 1982-05-27 Hoechst Ag, 6000 Frankfurt Verfahren zur herstellung von 3 (alpha) -hydroxy-5- (beta) -pregnan-11,20-dion
JPS58155098A (ja) * 1982-03-09 1983-09-14 Yakult Honsha Co Ltd 微生物によるウルソデオキシコ−ル酸の製造法
WO1990009394A2 (en) * 1989-02-07 1990-08-23 The Upjohn Company Dehalogenation of organic compounds using tin or lead
DE10113257C1 (de) 2001-03-19 2002-11-14 Inst Mikrotechnik Mainz Gmbh Elektrophoresevorrichtung und ihre Verwendung
ITMI20050912A1 (it) * 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
US20080318870A1 (en) 2007-06-19 2008-12-25 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
NZ734451A (en) * 2012-06-19 2018-12-21 Intercept Pharmaceuticals Inc Preparation, uses and solid forms of obeticholic acid
CA2912139C (en) 2013-05-14 2021-04-20 Roberto Pellicciari 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators
WO2016073767A1 (en) 2014-11-06 2016-05-12 Enanta Pharmaceuticals, Inc. Bile acid analogs an fxr/tgr5 agonists and methods of use thereof
JP2017535570A (ja) 2014-11-26 2017-11-30 エナンタ ファーマシューティカルズ インコーポレイテッド Fxr/tgr5アゴニストとしての胆汁酸類似体およびその使用方法
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
US11578097B2 (en) 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
MX2017010376A (es) 2015-02-11 2017-12-20 Enanta Pharm Inc Análogos de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos.
CA2981503C (en) 2015-03-31 2023-09-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
CN108137643A (zh) * 2015-08-07 2018-06-08 英特塞普特医药品公司 制备胆汁酸及其衍生物的方法
EP3981779A1 (en) * 2015-10-07 2022-04-13 Intercept Pharmaceuticals, Inc. Farnesoid x receptor modulators
CN107973834A (zh) 2016-10-22 2018-05-01 合帕吉恩治疗公司 作为fxr/tgr5调节剂的胆酸衍生物
WO2018081285A1 (en) 2016-10-26 2018-05-03 Enanta Pharmaceuticals, Inc. Urea-containing isoxazole derivatives as fxr agonists and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2020525426A5 (https=)
CN105518011B (zh) 氨基磷酸酯类衍生物制备方法及其中间体和中间体的制备方法
JP2022133462A5 (https=)
JP2010513494A5 (https=)
JP5371033B2 (ja) 3官能ニトリルオキシドおよびその製造方法
JP2013505259A5 (https=)
WO2006046499A1 (ja) インドリン化合物およびその製造方法
JP6322350B1 (ja) 新規トリチル保護剤
WO2012006964A1 (zh) 恩替卡韦的合成方法及其中间体化合物
KR102266680B1 (ko) 벨리노스테트의 다형태 및 이의 제조 방법
JP2019214626A5 (https=)
JP2018518486A5 (https=)
JP2008050321A (ja) 光分解性カップリング剤
JP6289479B2 (ja) 2−アミノ−4,6−ジメトキシベンズアミド及び他のベンズアミド化合物の合成方法
TWI343909B (en) Process for making galantamine
WO2002051781A1 (fr) Procede permettant de preparer un compose d'halohydrine optiquement actif
JP2016535039A5 (https=)
CN101220070B (zh) 肌苷及其制造方法
CN1216036C (zh) 手性氨基醇配体及其在端炔对亚氨的不对称加成中的应用
JP5204438B2 (ja) 含フッ素アミン化合物の製造方法
JP6887022B2 (ja) ケトライド化合物を製造するための方法
JP2020529457A5 (https=)
TWI361807B (en) Process for preparing substituted 4-alkoxycarbonyl-3-aminothiophenes
JP2017514846A5 (https=)
CN105198832A (zh) 一种盐酸阿考替胺的制备方法